According to a new report LAMEA Pharmacogenomics Market, published by KBV research, the LAMEA Pharmacogenomics Market would witness market growth of 9.9% CAGR during the forecast period (2019-2025).
The Brazil market dominated the LAMEA Electrophoresis Market by Country in 2018, growing at a CAGR of 9.6 % during the forecast period. The Argentina market is expected to witness a CAGR of 11.2% during (2019 - 2025). Additionally, The UAE market is expected to witness a CAGR of 9.9% during (2019 - 2025).
The Oncology market dominated the LAMEA Pharmacogenomics Market by Application in 2018, growing at a CAGR of 9.2 % during the forecast period. The Psychiatry market is expected to witness a CAGR of 10.4% during (2019 - 2025).
The Hospitals and Clinics market dominated the Argentina Pharmacogenomics Market by End User in 2018, thereby, achieving a market value of $57.2 million by 2025, growing at a CAGR of 10.2 % during the forecast period. The Research Institutions market is expected to witness highest CAGR of 10.9% during (2019 - 2025).
Full Report: https://www.kbvresearch.com/lamea-pharmacogenomics-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Abbott Laboratories, Empire Genomics LLC, Illumina, Inc., oneome LLC, Myriad Genetics Inc., Thermo Fisher Scientific, Inc., Teva Pharmaceuticals Industries Ltd., Bayer AG, Opko Health, Inc., and Becton, Dickinson and Company.
By Technology
By Application
By End User
By Country
Companies Profiled
Unique Offerings from KBV Research
Unique Offerings 
